Luitpold Pharmaceuticals, a New York-based subsidiary of Daiichi Sankyo, has signed a binding merger agreement with Roxro Pharma, a US Specialty pharmaceutical company, developing products for the treatment of acute pain conditions.
Roxro Pharma obtained FDA approval for Sprix (ketorolac tromethamine) nasal spray in May 2010, for the short-term (up to 5 days)management of acute moderate to moderately severe pain that requires analgesia at the opioid level.
Roxro Pharma said that Sprix is a prescription intranasal formulation of the analgesic ketorolac tromethamine (previously marketed as Toradol by Roche Laboratories), a non-steroidal anti-inflammatory drug (NSAID).
Sprix is designed to provide ambulatory patients with a convenient, potent, and fast-acting option for acute moderate to moderately severe pain relief.
Luitpold president and CEO Mary Jane Helenek said they believe that Sprix will be highly complimentary to Luitpold’s existing product line and our continuing strategy to diversify their product portfolio and further grow their US pharmaceutical business.
Roxro Pharma chairman and CEO Roberto Rosenkranz said they believe that Luitpold has the infrastructure, expertise and capabilities to successfully bring this novel treatment to patients with moderate to moderately severe acute pain.